MCID: BLR008
MIFTS: 44

Bilirubin Metabolic Disorder

Categories: Metabolic diseases

Aliases & Classifications for Bilirubin Metabolic Disorder

MalaCards integrated aliases for Bilirubin Metabolic Disorder:

Name: Bilirubin Metabolic Disorder 12 14
Hyperbilirubinemia 12 29 52 42 69
Hyperbilirubinemia, Hereditary 42 69
Hereditary Hyperbilirubinemia 12
Hyperbilirubinaemia 12

Classifications:



Summaries for Bilirubin Metabolic Disorder

Disease Ontology : 12 An inherited metabolic disorder that involves elevated levels of bilirubin resulting from disruption of bilirubin metabolism.

MalaCards based summary : Bilirubin Metabolic Disorder, also known as hyperbilirubinemia, is related to hyperbilirubinemia, familial transient neonatal and hyperbilirubinemia, rotor type, digenic, and has symptoms including icterus, polydipsia and muscle weakness. An important gene associated with Bilirubin Metabolic Disorder is UGT1A1 (UDP Glucuronosyltransferase Family 1 Member A1), and among its related pathways/superpathways are Porphyrin and chlorophyll metabolism and Glucose / Energy Metabolism. The drugs Glyburide and Metformin have been mentioned in the context of this disorder. Affiliated tissues include liver, bone and breast, and related phenotype is homeostasis/metabolism.

Related Diseases for Bilirubin Metabolic Disorder

Diseases related to Bilirubin Metabolic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 69)
id Related Disease Score Top Affiliating Genes
1 hyperbilirubinemia, familial transient neonatal 33.5 UGT1A UGT1A1 UGT1A6
2 hyperbilirubinemia, rotor type, digenic 12.2
3 congenital intrauterine infection-like syndrome 10.9
4 crigler-najjar syndrome, type i 10.8
5 dubin-johnson syndrome 10.8
6 gilbert syndrome 10.8
7 non-hodgkin lymphoma, during pregnancy 10.8 ALB F2
8 cardiomyopathy, dilated, 1o 10.7 ABCC2 SLCO1B1
9 smoking as a quantitative trait locus 2 10.7 HMOX1 HP
10 fragile x syndrome type 2 10.7 ALB F2
11 argyria 10.6 F2 GPT
12 porphyria, acute hepatic 10.6 ADAMTS13 HP
13 kozlowski brown hardwick syndrome 10.6 ALB G6PD
14 thalassemia-beta, dominant inclusion-body 10.5 F2 UGT1A1 UGT1A6
15 female infertility of uterine origin 10.5 ALB F2 GPT
16 oral cavity carcinoma in situ 10.5 ALB F2
17 hepadnavirus infection 10.5 ALB F2 GPT
18 microcephaly 8, primary, autosomal recessive 10.5 ALB F2 GPT
19 cutaneous fibrous histiocytoma 10.5 ALB F2 GPT
20 acute lymphocytic leukemia 10.5 ALB F2 GPT
21 hemolytic-uremic syndrome 10.5 ALB F2 GPT
22 egg allergy 10.5 F12 F2
23 congenital hypoplastic anemia 10.4 ALB F2 GPT
24 bladder sarcoma 10.4 ALB GPT HP
25 punctate epithelial keratoconjunctivitis 10.4 SLC35A2 UGT1A1 UGT1A6
26 bubonic plague 10.4 ALB F2 GPT
27 nodular degeneration of cornea 10.4 G6PD HP SLCO1B1 UGT1A1
28 alzheimer disease 6 10.4 ABCC1 ABCC2 SLCO1B1
29 spinocerebellar ataxia 8 10.4 ALB F2 GPT
30 kohler's disease 10.4 ALB F2 GPT UGT1A1
31 lacrimal system cancer 10.3 ADAMTS13 ALB F2
32 maxillary sinusitis 10.3 F2 GPT SLC35A2
33 seborrheic infantile dermatitis 10.3 ADAMTS13 HP
34 fallopian tube leiomyosarcoma 10.3 ALB F2 GPT HP
35 dermatomyositis 10.3 ALB GPT UGT1A1 UGT1A6
36 acute hydrops keratoconus 10.2 PKM SLCO1B1 UGT1A1 UGT1A6
37 alopecia 10.2 ADAMTS13 ALB F2 GPT
38 glandular cystitis 10.2 G6PD HMOX1 NR1I3 SLCO1B1 UGT1A1
39 kernicterus 10.1
40 acute proliferative glomerulonephritis 10.1 ADAMTS13 F2 GPT HP
41 tuberculum sellae meningioma 10.1 ALB F2 GGT1
42 raltegravir toxicity 10.1 SLCO1B1 UGT1A UGT1A1 UGT1A7
43 bartter disease 10.1 F2 GGT1 GPT
44 pyloric stenosis 10.1 F2 OXT
45 prostate cancer, progression and metastasis of 10.1 ALB F2 GGT1
46 toxic labyrinthitis 10.0 G6PD HP
47 pancreatic cystadenocarcinoma 10.0 ALB F2 GGT1 GPT
48 paranasal sinus sarcoma 10.0 ALB F2 GGT1 GPT
49 isthmus cancer 10.0 ALB F2 GGT1 GPT
50 noninfectious dermatoses of eyelid 10.0 ALB F2 GGT1 GPT

Graphical network of the top 20 diseases related to Bilirubin Metabolic Disorder:



Diseases related to Bilirubin Metabolic Disorder

Symptoms & Phenotypes for Bilirubin Metabolic Disorder

UMLS symptoms related to Bilirubin Metabolic Disorder:


icterus, polydipsia, muscle weakness, jaundice (not of newborn)

MGI Mouse Phenotypes related to Bilirubin Metabolic Disorder:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.4 ABCC1 ABCC2 ADAMTS13 ALB F12 F2

Drugs & Therapeutics for Bilirubin Metabolic Disorder

Drugs for Bilirubin Metabolic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 190)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Glyburide Approved Phase 4 10238-21-8 3488
2
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 14219 4091
3
Pioglitazone Approved, Investigational Phase 4,Phase 3 111025-46-8 4829
4
Deferasirox Approved, Investigational Phase 4,Phase 2 201530-41-8 5493381
5
Iron Approved Phase 4,Phase 2 7439-89-6 23925
6
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2 22916-47-8 4189
7
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
8
Zinc Approved Phase 4,Phase 3 7440-66-6 32051 23994
9
Insulin Aspart Approved Phase 4,Phase 3 116094-23-6 16132418
10
Insulin Detemir Approved Phase 4 169148-63-4 5311023
11
Calcium Carbonate Approved Phase 4 471-34-1
12
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Early Phase 1 59-30-3 6037
13
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
14
Nicotinamide Approved, Nutraceutical Phase 4 98-92-0 936
15 Antioxidants Phase 4,Phase 2,Phase 1,Early Phase 1
16
Bilirubin Phase 4,Phase 3,Phase 1 635-65-4 5280352
17 Pharmaceutical Solutions Phase 4,Phase 2
18 Protective Agents Phase 4,Phase 2,Phase 1,Early Phase 1
19 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Phase 1
20 insulin Phase 4,Phase 3
21 Insulin, Globin Zinc Phase 4,Phase 3
22 Liver Extracts Phase 4,Phase 2
23 Antifungal Agents Phase 4,Phase 2
24 Anti-Infective Agents Phase 4,Phase 2,Phase 1
25 Antirheumatic Agents Phase 4,Phase 2,Early Phase 1
26 Calcineurin Inhibitors Phase 4
27 Chelating Agents Phase 4,Phase 2
28 Cyclosporins Phase 4
29 Dermatologic Agents Phase 4,Phase 2,Early Phase 1
30 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Early Phase 1
31 Iron Chelating Agents Phase 4,Phase 2
32 Dipeptidyl-Peptidase IV Inhibitors Phase 4,Phase 3
33 HIV Protease Inhibitors Phase 4,Phase 3,Phase 1
34
protease inhibitors Phase 4,Phase 3,Phase 1
35 Insulin degludec, insulin aspart drug combination Phase 4,Phase 3
36 Insulin, Isophane Phase 4
37 Insulin, Long-Acting Phase 4,Phase 3
38 Isophane insulin, beef Phase 4
39 Isophane Insulin, Human Phase 4
40 Protamines Phase 4
41 Antacids Phase 4,Phase 1
42 Antimetabolites Phase 4,Phase 3,Phase 2,Early Phase 1
43 Anti-Ulcer Agents Phase 4,Phase 1
44 Bone Density Conservation Agents Phase 4,Phase 3
45 Calcium, Dietary Phase 4,Phase 3,Phase 2
46 Gastrointestinal Agents Phase 4,Phase 2,Phase 1
47 Hypolipidemic Agents Phase 4,Phase 3,Phase 2
48 Lipid Regulating Agents Phase 4,Phase 3,Phase 2
49 Micronutrients Phase 4,Phase 3
50 Trace Elements Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 73)

id Name Status NCT ID Phase Drugs
1 Efficacy of Yinzhihuang Oral Liquid on Indirect Bilirubin of Neonates With Glucose-6-phosphate Dehydrogenase Deficiency Unknown status NCT02594904 Phase 4 Yinzhihuang Oral Liquid
2 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
3 Safety Study of Pioglitazone Compared To Glyburide on Liver Function Completed NCT00494312 Phase 4 Pioglitazone;Glyburide
4 Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients Completed NCT01818726 Phase 4 ICL670A and standard immunosupressive therapy (Cyclosporine A);Immunosupressive therapy (Cyclosporine A)
5 Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes Completed NCT01862263 Phase 4 Vildagliptin;Insulin;Placebo
6 Comparison of the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After Insulin Treatment Completed NCT00795600 Phase 4 insulin detemir;insulin NPH
7 Oral Versus Intravenous Rehydration for Prevention of Dehydration in Premature Babies, During the First Days of Life. Completed NCT00715000 Phase 4
8 Nicotinic Acid in Hemodialysis Patients With Hyperphosphatemia Recruiting NCT02836184 Phase 4 Nicotinic Acids;Calcium Carbonate
9 Cardioprotective Effects of Green Tea Versus Maté Intake Unknown status NCT00933647 Phase 3
10 A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipid Completed NCT01674712 Phase 3 Fixed Combination of Fenofibrate/simvastatin 145/20 mg;Simvastatin 20 mg;Fenofibrate 145 mg;Fixed Combination of Fenofibrate/simvastatin 145/40 mg;Simvastatin 40 mg
11 A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density Completed NCT00515463 Phase 3
12 Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM Completed NCT00736099 Phase 3 linagliptine 5 mg;linagliptine 5 mg and pioglitazone 30 mg
13 Safety and Efficacy of Long-Term Treatment With Atorvastatin in Patients With Primary Biliary Cirrhosis Completed NCT00844402 Phase 3 Atorvastatin
14 A Study in Patients With Type 2 Diabetes Mellitus Completed NCT01435616 Phase 3 Glargine;LY2605541
15 A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab Completed NCT01457950 Phase 3 denosumab;placebo;open-label denosumab
16 Denosumab China Phase III Study Completed NCT02014467 Phase 3 Denosumab;Placebo
17 A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab Completed NCT01495000 Phase 3 denosumab;placebo
18 A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH) Completed NCT00730236 Phase 3 AEGR-733
19 Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes Recruiting NCT03268005 Phase 3 Faster-acting insulin aspart;Insulin aspart;Insulin degludec;Metformin
20 Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes Recruiting NCT02868177 Phase 2, Phase 3
21 An Efficacy and Safety Study of Fixed-dose Rosiglitazone/Glimepiride to Treat Chinese Type 2 Diabetes Patients Terminated NCT01453049 Phase 3 rosiglitazone/glimepiride fix dose combination;glimepiride
22 A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic Hyponatremia Withdrawn NCT02442674 Phase 3 Tolvaptan
23 The Anti-Diabetic and Cholesterol-Lowering Effects of Cinnamon and Cassia Bark Unknown status NCT00479973 Phase 2
24 A Study to Assess ARI-3037MO on Hepatic Fat Metabolism in Patients With Dysglycemia and Evidence of Hepatic Steatosis Unknown status NCT02574325 Phase 2 Placebo;ARI-3037MO
25 Safety and Efficacy of Clenbuterol in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy Completed NCT01942590 Phase 1, Phase 2 Clenbuterol;Placebo
26 Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients Completed NCT01020123 Phase 2 AZD1656;Placebo;Glipizide
27 A Clinical Study to Assess the Safety, Tolerability, and Activity of Oral SRT2104 Capsules Administered for 28 Days to Subjects With Type 2 Diabetes Mellitus Completed NCT01018017 Phase 2 Placebo;SRT2104
28 The Effect of a Low Glycemic Index Diet on Blood Sugar Control in Women With Gestational Hyperglycemia Completed NCT00314717 Phase 2
29 Micellar Curcumin and Metabolic Syndrome Biomarkers Completed NCT01925547 Phase 2
30 A Phase II, Double-blinded, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Vitalliver in Patients With Decompensated Cirrhosis Completed NCT00562783 Phase 2 Vitaliver;Placebo
31 Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor Completed NCT01556906 Phase 2 Lomitapide
32 A Randomized, Double-Blind Trial Comparing the Efficacy and Safety of Fenofibrate, Metformin, Their Combination and Placebo in Patients With Metabolic Syndrome. Completed NCT00703755 Phase 2 Fenofibrate /Metformin;Fenofibrate /Metformin;Fenofibrate /Metformin;Fenofibrate /Metformin;Fenofibrate /Metformin;Fenofibrate /Metformin;Placebo
33 The Efficacy and Safety of the Xue-Fu-Zhu-Yu Capsule in Treatment of Qi Stagnation and Blood Stasis Syndrome. Recruiting NCT03091634 Phase 2 xue-fu-zhu-yu capsule;xue-fu-zhu-yu capsule simulated agent
34 A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent Beta-Thalassemia Recruiting NCT03271541 Phase 2 Bitopertin
35 Gene Transfer Clinical Study in Crigler-Najjar Syndrome Recruiting NCT03223194 Phase 1, Phase 2
36 Runihol in Nonalcoholic Fatty Liver Disease and Metabolic Syndrome Recruiting NCT02930161 Phase 2 Runihol
37 Efficacy and Safety Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Orthotopic Liver Transplantation Patients Active, not recruiting NCT03031470 Phase 2 Reparixin
38 Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus Active, not recruiting NCT02455011 Phase 1, Phase 2
39 Efficacy and Safety Study of WTX101 in Adult Wilson Disease Patients Active, not recruiting NCT02273596 Phase 2 WTX101
40 Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Active, not recruiting NCT01829503 Phase 2 decitabine and cytarabine
41 Investigating Re-Dosing With Otelixizumab in Adults With Newly-Diagnosed Type 1 Diabetes Mellitus Terminated NCT01222078 Phase 2
42 Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome Terminated NCT01892644 Phase 2 Deferasirox;Deferasirox
43 Methylprednisolone N Acetylcysteine in Hepatic Resections Terminated NCT01726465 Phase 2 Methylprednisolone;N-acetylcysteine
44 A Pilot Study of Moderate Hyperbilirubinemia in Type 1 Diabetes Mellitus Completed NCT01421355 Phase 1 Atazanavir
45 Drug Interaction Study Between AZD3480 and Cytochrome P450 Completed NCT00692510 Phase 1 AZD3480;Placebo;Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)
46 Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus Completed NCT02715193 Phase 1
47 Assessment of Severity and Prognosis in Elderly Patients With COPD and Complex Chronic Comorbidities Unknown status NCT01893918
48 Determining Prevalence of Acute Bilirubin Encephalopathy in Developing Countries Completed NCT01754688
49 Orlistat Treatment of Crigler-Najjar Disease Completed NCT00461799 orlistat
50 Does Maternal Instruction Prevent Kernicterus in Nigeria? Completed NCT02713464

Search NIH Clinical Center for Bilirubin Metabolic Disorder

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: hyperbilirubinemia

Genetic Tests for Bilirubin Metabolic Disorder

Genetic tests related to Bilirubin Metabolic Disorder:

id Genetic test Affiliating Genes
1 Hyperbilirubinemia 29

Anatomical Context for Bilirubin Metabolic Disorder

MalaCards organs/tissues related to Bilirubin Metabolic Disorder:

39
Liver, Bone, Breast, Skin, Endothelial, Myeloid

Publications for Bilirubin Metabolic Disorder

Variations for Bilirubin Metabolic Disorder

ClinVar genetic disease variations for Bilirubin Metabolic Disorder:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 F12 NM_000505.3(F12): c.983C> G (p.Thr328Arg) single nucleotide variant Pathogenic rs118204456 GRCh37 Chromosome 5, 176831232: 176831232
2 UGT1A1 UGT1A1*6 single nucleotide variant drug response rs4148323 GRCh37 Chromosome 2, 234669144: 234669144
3 UGT1A1 NM_000463.2(UGT1A1): c.1456T> G (p.Tyr486Asp) single nucleotide variant Pathogenic rs34993780 GRCh37 Chromosome 2, 234681059: 234681059
4 UGT1A1 NM_000463.2(UGT1A1): c.1084+1G> T single nucleotide variant Pathogenic rs587784535 GRCh38 Chromosome 2, 233767937: 233767937
5 UGT1A1 NM_000463.2(UGT1A1): c.238_239insGTAC (p.Pro80Argfs) insertion Pathogenic rs797046090 GRCh37 Chromosome 2, 234669171: 234669172
6 UGT1A1 NM_000463.2(UGT1A1): c.722_723delAG (p.Glu241Glyfs) deletion Pathogenic rs797046091 GRCh38 Chromosome 2, 233761009: 233761010

Expression for Bilirubin Metabolic Disorder

Search GEO for disease gene expression data for Bilirubin Metabolic Disorder.

Pathways for Bilirubin Metabolic Disorder

Pathways related to Bilirubin Metabolic Disorder according to GeneCards Suite gene sharing:

(show all 20)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.3 HMOX1 UGT1A1 UGT1A6 UGT1A7
2 12.22 ABCC1 ABCC2 G6PD HMOX1 PKM UGT1A1
3
Show member pathways
11.66 ABCC2 SLCO1B1 UGT1A1
4 11.66 ABCC2 G6PD GGT1 HMOX1 UGT1A1 UGT1A6
5
Show member pathways
11.61 ABCC2 UGT1A1 UGT1A6
7
Show member pathways
11.48 UGT1A1 UGT1A6 UGT1A7
8
Show member pathways
11.44 NR1I3 UGT1A1 UGT1A7
9
Show member pathways
11.37 ABCC2 NR1I3 UGT1A1 UGT1A6
10 11.31 UGT1A1 UGT1A6 UGT1A7
11 11.06 ABCC2 NR1I3 UGT1A1 UGT1A6
12
Show member pathways
10.99 ABCC2 SLCO1B1 UGT1A1
13
Show member pathways
10.88 ABCC1 ABCC2 SLCO1B1
14 10.85 ABCC1 ABCC2
15
Show member pathways
10.84 ABCC1 ABCC2 SLCO1B1 UGT1A1 UGT1A6 UGT1A7
16 10.79 G6PD GPT
17 10.77 ABCC2 NR1I3 SLCO1B1
18 10.75 ABCC1 UGT1A1
19 10.67 ABCC1 ABCC2
20 10.51 ABCC1 ABCC2

GO Terms for Bilirubin Metabolic Disorder

Cellular components related to Bilirubin Metabolic Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.65 ABCC1 ALB F12 F2 G6PD GGT1
2 extracellular space GO:0005615 9.28 ADAMTS13 ALB F12 F2 GGT1 GPT

Biological processes related to Bilirubin Metabolic Disorder according to GeneCards Suite gene sharing:

(show all 15)
id Name GO ID Score Top Affiliating Genes
1 hemostasis GO:0007599 9.58 ADAMTS13 F12 F2
2 blood coagulation, intrinsic pathway GO:0007597 9.55 F12 F2
3 retinoic acid metabolic process GO:0042573 9.54 UGT1A1 UGT1A7
4 leukotriene metabolic process GO:0006691 9.52 ABCC1 GGT1
5 ATP hydrolysis coupled anion transmembrane transport GO:0099133 9.51 ABCC1 ABCC2
6 acute-phase response GO:0006953 9.5 F2 HP UGT1A1
7 positive regulation of blood coagulation GO:0030194 9.49 F12 F2
8 zymogen activation GO:0031638 9.48 F12 GGT1
9 thyroid hormone transport GO:0070327 9.46 ABCC2 SLCO1B1
10 heme catabolic process GO:0042167 9.43 HMOX1 UGT1A1
11 response to steroid hormone GO:0048545 9.43 ABCC2 OXT UGT1A1
12 flavone metabolic process GO:0051552 9.37 UGT1A1 UGT1A7
13 cellular glucuronidation GO:0052695 9.33 UGT1A1 UGT1A6 UGT1A7
14 xenobiotic glucuronidation GO:0052697 9.13 UGT1A1 UGT1A6 UGT1A7
15 flavonoid glucuronidation GO:0052696 8.62 UGT1A1 UGT1A7

Molecular functions related to Bilirubin Metabolic Disorder according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transferase activity, transferring hexosyl groups GO:0016758 9.33 UGT1A1 UGT1A6 UGT1A7
2 ATPase-coupled anion transmembrane transporter activity GO:0043225 9.26 ABCC1 ABCC2
3 glucuronosyltransferase activity GO:0015020 9.13 UGT1A1 UGT1A6 UGT1A7
4 retinoic acid binding GO:0001972 8.8 UGT1A1 UGT1A6 UGT1A7

Sources for Bilirubin Metabolic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....